Are peptides legal? Yes — and the useful answer is more specific than that.
Men ask this because they can feel that something about the category is unsettled, and they’re right — but not for the reason they usually think. No law makes peptides illegal. What exists is a framework with three separate moving parts, and nearly all of the confusion comes from those three collapsing into one. Sorted out, the line between medicine and everything else sharing the same chemical names becomes obvious.
Castellano Health Institute · Serving Orange County
Almost all the confusion is three questions collapsing into one.
Someone asking whether peptides are legal is usually asking all three of these at once and hearing an answer to only one. Each has a different answer, and each is answered by a different part of the system.
Is this medicine approved for this use?
A question about one drug and one indication — answered by FDA's approval process, not by the substance's chemistry.
May this substance lawfully be compounded?
A separate question with its own federal framework, its own conditions, and its own list — and the one that moves most often.
May a physician prescribe it to this patient?
A question about medical judgment and a legitimate clinical basis for the specific man in the chair.
Approval is a statement about one medicine for one specific use.
Before a drug is approved, the company behind it submits clinical data showing the drug is safe and effective for its intended use, and FDA evaluates whether the benefits of that use outweigh the risks. The approval that comes out the other end is narrow by design — one medicine, one condition, one dose and route. So “is it approved” is never a yes-or-no question about a whole category. It is a question about one medicine and one indication at a time, and several peptide-based medicines carry exactly that kind of approval.
Approval also doesn’t end the physician’s judgment. FDA’s own patient-facing guidance puts it plainly: once FDA approves a drug, healthcare providers generally may prescribe it for an unapproved use when they judge that it is medically appropriate for their patient. That is the practice commonly called “off-label,” it is lawful, and it happens across every field of medicine. The honest footnote belongs beside it — used that way, the drug has not been evaluated by FDA for that particular use. It is a real limit on what the approval covers, and a patient deserves to hear it stated rather than discover it.
Compounded medicine is its own legal category.
Compounding is a licensed pharmacist or physician combining, mixing, or altering ingredients to create a medication tailored to an individual patient. It exists because approved products don’t fit every patient — a dye allergy, a dose nobody manufactures, a form a person can actually take. A great deal of peptide therapy sits in this category rather than the approved-product category, which is exactly why the two get confused. Federal law describes two lanes, and knowing which one a prescription came through tells you who is accountable for it.
| The lane | Who it covers | How it’s overseen |
|---|---|---|
| Section 503A | State-licensed pharmacies and licensed physicians, compounding for an identified individual patient against a valid prescription. | Day-to-day oversight of those pharmacies sits primarily with state boards of pharmacy. FDA also conducts surveillance and for-cause inspections. |
| Section 503B | Outsourcing facilities — a category established by the Drug Quality and Security Act in 2013 — compounding under the supervision of a licensed pharmacist. | These facilities register with FDA, are inspected by FDA on a risk-based schedule, and are subject to current good manufacturing practice requirements. |
Within the first lane the conditions are specific. The exemption applies to a product compounded for an identified individual patient based on the receipt of a valid prescription order. The raw substance has to clear one of three gates: it complies with an applicable United States Pharmacopeia or National Formulary monograph if one exists; or, if none exists, it is a component of an FDA-approved drug product; or, failing both, it appears on FDA’s published 503A bulks list. It must also come from an FDA-registered establishment and arrive with a valid certificate of analysis.
And the honest headline over all of it: compounded drugs are not FDA-approved. The agency does not verify the safety, effectiveness, or quality of a compounded drug before it is marketed. That is worth saying out loud, because it is precisely why the rest of the chain — licensed pharmacy, registered supplier, certificate of analysis, a physician reading the labs — is doing real work rather than ceremonial work.
The permissible list is not static — which is why this practice publishes no menu.
Substances can be nominated for the 503A bulks list, and while FDA works through the nominations it has sorted them under an interim policy into categories. One of those covers substances where the agency has identified significant safety risks relating to their use in compounding pending further evaluation; when a substance lands there, FDA publishes the safety information describing those risks. It is a documented, public process.
That process has moved, and it has moved on peptides specifically. A group of peptide substances was placed into the significant-safety-risk category in September 2023, and a further set of nominated peptide substances was subsequently withdrawn by the parties that nominated them. FDA has also stated in guidance that it does not intend to place substances nominated on or after January 7, 2025 into these categories at all.
That is the framework working through a category the evidence base is still catching up to, and it has a direct consequence for how a practice talks to patients. A list that moves cannot honestly be published as a fixed menu. It is why the peptide therapy page describes categories rather than names, and why the recommendation for a specific patient is made in the visit, against current guidance, after the labs are read.
A prescription and a purchase are not the same transaction.
This is where the legal question becomes a practical one. Two things can share a chemical name and have nothing else in common. A compounded prescription, prepared by a licensed pharmacy under physician oversight for a patient that physician has actually evaluated, is a category of medical care: a diagnosis behind it, a prescription written for one named person, a pharmacy answerable to a licensing board, a supplier of record, and a doctor who will read the follow-up bloodwork.
Product acquired outside that chain has none of those — no examining physician, no prescription, no licensed pharmacy standing behind what is in the vial, no verification of identity, purity, or dose. That is not a cheaper version of the same care and it is not a shortcut through it. It is an unregulated transaction rather than a category of medical care, and the difference is not one of degree. It is the same distinction that runs through the practice’s anabolic steroid care page.
What lawful looks like from the patient’s side.
You shouldn’t have to read federal statute to tell whether the care in front of you is the real thing. These are the visible markers — the parts a patient can see from the chair.
- A real evaluation first — history, symptoms, and bloodwork before any recommendation exists
- A physician willing to say the category isn't indicated for you, and to say it in the first visit
- A prescription written for you specifically, not a product selected off a page
- A licensed pharmacy preparing it, accountable to a board that can inspect it
- A defined protocol length with a scheduled re-evaluation, not an open-ended auto-refill
- A documented record the same physician reads again at the next visit
The last one is the quiet load-bearing item. A protocol is only as sound as the follow-up attached to it — which is why the legal question and the safety question turn out to be the same question in different clothes. That side of it is laid out on are peptides safe.
The legality questions men ask first.
Don’t see yours? Call the office and ask Dr. Castellano directly.
Are peptides legal in the US?
Are peptides FDA-approved?
Why don't you list specific peptides on the website?
Is a prescription required for peptide therapy?
What is a compounding pharmacy?
Does the law around peptides change?
Is peptide therapy legal in California?
Related in the peptides knowledge cluster.
Peptide Therapy with Dr. Castellano
The service page — how peptide therapy is evaluated and practiced here.
Are Peptides Safe?
Side effects, sourcing, and why oversight is where the real risk sits.
Peptides vs. TRT
Which problem each one actually solves, and why 'instead of' is usually the wrong question.
Anabolic Steroid Care
The same straight-talk posture, for men who've already been down a different road.
Ask the legal question out loud.
It is a fair question with a real answer, and a practice that can’t give it to you plainly is telling you something. At Castellano Health Institute the conversation about whether peptide therapy belongs in your plan happens in the visit, against current guidance, with your bloodwork on the table — and sometimes the honest answer is that this category isn’t where your problem lives. You’ll hear that from the same physician who would have prescribed it. Call the office to schedule a consultation.
Mon–Fri 9 AM – 5 PM · Serving Orange County